Resources

This fact sheet from the Global Health Technologies Coalition examines how US leadership in global health research helps to saves lives worldwide and provides domestic economic benefits.

This brief summarizes key findings from a literature review conducted by PATH to identify published and gray literature reporting international experiences with the Uniject™ injection system. The findings shed light on user acceptability and highlight potential cost savings in terms of training time, waste management, and reduction in drug wastage when Uniject is used instead of a standard autodisable syringe. This document synthesizes the experience and evidence on the use of Uniject worldwide with medicines such as the injectable contraceptive Cyclofem®, hepatitis B and tetanus toxoid vaccines, as well as the drug oxytocin, which is used to prevent postpartum hemorrhage.

This brief describes results from an analysis conducted by PATH comparing the current intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with a new formulation packaged in the Uniject™ injection system. The analysis focused on waste management implications, identifying key quantitative and qualitative differences between the two products.

This brief summarizes the strategic demand models developed by PATH and the Futures Institute for the injectable contraceptive depo-subQ provera 104™ in the Uniject™ injection system (depo-subQ in Uniject) in Kenya, Malawi, Pakistan, Rwanda, and Senegal. These models will help inform global and country introduction planning for depo-subQ in Uniject.

This fact sheet provides an overview of the impact that global and national investment have had in the fight against malaria, with an emphasis on the importance of US support for the President’s Malaria Initiative and the Global Fund to Fight AIDS, Tuberculosis and Malaria.